Ligand Pharmaceuticals Reaches Analyst Target Price
July 21, 2016 at 09:51 AM EDT
In recent trading, shares of Ligand Pharmaceuticals Inc (LGND) have crossed above the average analyst 12-month target price of $134.40, changing hands for $135.12/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..